疾患詳細

疾患詳細



LDL の存在下で培養された皮膚線維芽細胞での filipin 染色と蛍光顕微鏡でみえる非エステル化コレステロールの蓄積. (a) 古典的 NiemannPick C型 (NPC) 細胞; (b) バリアント NPC 細胞; (c) 正常細胞. (Vanier MT et al. Clin. Genet. 64: 269-281, 2003)

#257220
Niemann-Pick disease, type C1 (NPC1)
(Niemann-Pick disease, type C; NPC)
(Niemann-Pick disease with cholesterol esterification block)
(Niemann-PickP disease, subacute juvenile form)
(Niemann-Pick disease, chronic neuropathic form)
(Niemann-Pick disease without sphingomyelinase deficiency)
(Neurovisceral storage disease with vertical supranuclear ophthalmoplegia)
(Niemann-Pick disease, type D, included)
(Niemann-Pick disease, Nova Scotian type, included)

Niemann-Pick 病C1型
(Niemann-Pick 病C型)
(Niemann-Pick 病-コレステロールエステル化障害)
(Niemann-Pick 病, 亜急性若年型
(Niemann-Pick 病, 慢性ニューロパチー型)
(Niemann-Pick 病, sphingomyelinase 欠乏なし)
(神経内臓蓄積症-垂直核上性眼筋麻痺)
(Niemann-Pick 病D型, 含む)
(Niemann-Pick 病, Nova Scotian 型, 含む)
指定難病19 ライソゾーム病
小児慢性特定疾病 代89 ニーマン・ピック(Niemann-Pick)病

責任遺伝子:607623 NPC intracellular cholesterol transporter 1 (NPC1) <18q11.2>
遺伝形式:常染色体劣性

(症状)
(GARD)
 <80%-99%>
 Ataxia (運動失調) [HP:0001251] [028]
 Cognitive impairment (認知障害) [HP:0100543] [0123]
 Developmental regression (発達退行) [HP:0002376] [0125]
 Dystonia (ジストニア) [HP:0001332] [0240]
 Gait disturbance (歩行障害) [HP:0001288] [028]
 Global developmental delay (全般的発達遅滞) [HP:0001263] [0120]
 Hepatomegaly (肝腫) [HP:0002240] [01813]
 Jaundice (黄疸) [HP:0000952] [01810]
 
 <30%-79%>
 Aplasia/Hypoplasia of the abdominal wall musculature (腹壁筋無形成/低形成) [HP:0010318] [1200]
 Dysarthria (構音障害) [HP:0001260] [0230]
 Dysphagia (嚥下障害) [HP:0002015] [01820]
 Dysphonia (発声困難) [HP:0001618] [02371]
 Sleep disturbance (睡眠障害) [HP:0002360] [0152]
 Splenomegaly (脾腫) [HP:0001744] [01817]
 
 <5%-29%>
 Abnormal pyramidal sign (錐体路サイン異常) [HP:0007256] [02140][01405][0213][0241][0242][02613][0274]
 Ascites (腹水) [HP:0001541] [01802]
 Chorea (舞踏病) [HP:0002072] [02600]
 Seizures (けいれん) [HP:0001250] [01405]
 Tremor (振戦) [HP:0001337] [02604]
 
 
 Abnormal circulating cholesterol concentration (コレステロール濃度異常) [HP:0003107] [2017]
 Autosomal recessive inheritance (常染色体劣性遺伝) [HP:0000007]
 Bone-marrow foam cells (骨髄泡沫細胞) [HP:0004333] [2204]
 Cataplexy (カタプレキシー) [HP:0002524] [0206]
 Dementia (認知症) [HP:0000726] [0123]
 Fatal liver failure in infancy (乳児期の致死性肝不全) [HP:0006583] [01811]
 Fetal ascites (胎児腹水) [HP:0001791] [01802]
 Foam cells in visceral organs and CNS (内蔵および中枢神経の泡沫細胞) [HP:0003640]
 Generalized hypotonia (全身性筋緊張低下) [HP:0001290] [0242]
 Intellectual disability (知的障害) [HP:0001249] [0120]
 Loss of speech (発語喪失) [HP:0002371] [0233]
 Low cholesterol esterification rate (コレステロールエステル化比率低下) [HP:0003349]
 Muscular hypotonia (筋緊張低下) [HP:0001252] [0242]
 Neurofibrillary tangles (神経線維のもつれ) [HP:0002185]
 Neuronal loss in central nervous system (中枢神経系ニューロン喪失) [HP:0002529]
 Prolonged neonatal jaundice (遷延性新生児黄疸) [HP:0006579] [01810]
 Psychosis (精神病) [HP:0000709] [0206]
 Sea-blue histiocytosis (海青組織球症) [HP:0001982] [2208]
 Spasticity (痙縮) [HP:0001257] [0241]
 Vertical supranuclear gaze palsy (垂直の核上性注視麻痺) [HP:0000511] [0698]

(UR-DBMS)
【一般】発達遅滞 (乳児期後半で発症), 学業不良
 認知症
 成長遅滞
 けいれん
 肺炎
 呼吸障害
 胎児腹水
 遷延性黄疸 (1/4)
 *中等度の肝腫
 *中等度の脾腫
 死亡 by 3-9 y耳介
 乳児期の致死性肝不全 (まれ)
 嚥下障害
 知能悪化
 認知症
【神経】小脳性運動失調
 小脳サイン
 アテトーゼ
 筋緊張低下
 構音障害
 言語喪失
 痙縮
 ジストニア
 カタプレキシー
 神経線維濃縮体
 行動異常
 精神病
【眼】チェリー・レッド斑 (若年患者で), 斜視
 垂直の核上注視麻痺
【胸郭】肺浸潤
【皮膚】栄養失調
 (丘疹状または結節性皮膚黄色腫)
【検査】sphingomyelinase 活性は正常または軽度低下
 コレステロールエステル化率低下
 異常なコレステロールホメオスターシス
 内臓器官と中枢神経での泡沫細胞
 泡沫細胞は電顕で層状オスミウム好性膜からなる多形性細胞質封入体を含む
【血液学】骨髄 / 肝 / 脾の泡沫細胞
 'Sea-blue' 組織球
 貧血
 リンパ球空胞化
 *異常な細胞内スフィンゴミエリン蓄積
 脾機能亢進
【その他】遺伝的異質性 (→ NPC2, 607625)
 疾患は通常早期小児期に明らかとなる
 死亡は通常10歳代である
 多様な表現型がある
 4大グループ: 早期乳児型, 後期乳児型, 若年型, 成人型
 より早い進行と短い寿命を伴うより早い発症
 頻度 1/150,000 生産児
 頻度 1% (Yarmouth County, Nova Scotia)
 推定保因者頻度 (Yarmouth County, Nova Scotia)
 Nova Scotian バリアント (D型) は NPC1 の遺伝的隔離と考えられておりNPC1変異を伴う (607623.0004)

(A 型) 急性ニューロパチー型
(B 型) 慢性型
 神経病変なし
(C 型) 慢性ニューロパチー型
(D 型) Nova Scotia 亜型
(E 型) 成人非ニューロパチー型
(F 型) 海青組織球型

(要約)
●Niemann–Pick 病は, 致死性遺伝性代謝性疾患で, リソソーム蓄積症に含まれる
●症状
 症状はSphingomyelinが蓄積する器官に関連する
 肝脾腫:食思不振, 腹部膨満, 腹痛, 血小板減少
 中枢神経:失調歩行, 構音障害, 嚥下障害
 基底核機能障害:ジストニア
 上部脳幹:核上性注視麻痺
 より広範な大脳皮質や皮質下の病変:痴呆, けいれん
 骨髄:腔の拡大, 皮質骨菲薄化
 内反股
 発作性カタプレキシー
 逆睡眠
●原因
 SMPD1 遺伝子変異→ Niemann–Pick 病A型とB型
 NPC1 と NPC2 遺伝子変異→ Niemann-Pick 病 C型 (D型も含む)
●分類 (1961)
 Niemann–Pick disease type A: 古典的乳児
 Niemann–Pick disease type B: 内臓
 Niemann-Pick disease, type C: 亜急性/若年性
 Niemann–Pick disease type D: Nova Scotian 地域
●現在の分類
 Niemann-Pick 病, SMPD1-関連:A型とB型を含む
 Niemann-Pick 病 C型:C1型とC2型 (D型はC1型と同じ遺伝子変異)
●機序
●古典的乳児性A型:ミスセンス変異がsphingomyelinase の完全欠損を生じる
 Sphingomyelin は, 小器官膜を含む細胞膜成分なので, 酵素欠損は脂質分化をブロックし, マクロファージ-単球貪食細胞系のリソソーム内にsphingomyelin の蓄積を生じる
 細胞はsphingomyelin とコレステロールによるリソソーム膨張により拡大する
 組織学的には, 骨髄に脂肪をもつマクロファージと病理検査で, "sea-blue histiocytes" を証明する
 多数の小さな比較的一定したサイズの空胞が形成され, 細胞質は泡沫概観を呈する
●治療:支持療法に限定
 臓器移植の効果は限定的
 骨髄移植の試み
 Zavesca (Miglustat) がNPCに欧州で承認
 CYCLO (2-hydroxypropyl-β-cyclodextrin or HPBCD)のトライアル
●予後
 A型は極めて不良 (18か月までに死亡)
 B型とC型は10歳代〜成人まで生存

<小児慢性特定疾病 代89 ニーマン・ピック(Niemann-Pick)病>
概要・定義
ニーマン・ピック(Niemann-Pick)病は, 酸性スフィンゴミエリナーゼが欠損するA型, B型とNPC1またはNPC2蛋白の異常によって起こるC型に分類される。いずれも常染色体劣性遺伝形式を示す遺伝病である。肝臓, 脾臓, 骨髄の網内系細胞と神経細胞にスフィンゴミエリン, コレステロール, 糖脂質などが蓄積する。発症頻度は12万人に1人とされる。A型は乳児期に発症し, 肝脾腫, 精神運動障害, 垂直方向の眼球運動障害が見られる。B型は小児期に発症し, 肝脾腫が主体であり, 神経症状は伴わない。C型の発症年齢は様々で, 肝脾腫, カタレプキシー, 垂直眼球運動障害, 失調, ジストニア, 痴呆などの神経症状を呈する。成人発症では痴呆, 抑うつ症状などの精神症状を主体とする例もある。
疫学
日本ではA型とB型の罹患率は, 10万人あたり0.5人-1人とされており, B型の患者さんの方が比較的多い。C型の発症頻度は12万人に1人とされる。
病因
A型, B型の原因はSPD1(sphingomylelin phosphodiesterase 1)遺伝子の変異による。点変異, 欠失, スプライス異常など100以上の遺伝子変異が報告されている。C型は, NPC1遺伝子またはNPC2遺伝子の変異による。NPC遺伝子は, 細胞内コレステロール輸送に関係する遺伝子であるが, 細胞内には遊離型コレステロールのみならず, GM1ならびにGM2などのガングリオシドなど蓄積する。
症状
 A型は, 乳児期早期から肝脾腫が著明であり, 筋緊張低下, 哺乳障害, 嘔吐などが出現するし, 成長障害が認められる。6ヶ月以降, 精神運動発達障害が明らかとなり, 急速に神経症状が進行する。症状が進行した患者では, 眼底にチェリー・レッドスポットが見られる。
 B型は, A型よりも症状は軽く小児期以降に発症する。肝脾腫が初発症状であることも多い。肝脾腫の程度は様々であり, 肝障害が進行し, 肝硬変, 門脈圧亢進, 腹水を伴うこともある。また, 血液検査では低HDL血症が特徴的で, 脾機能亢進により血小板減少が認められることがある。胸部X線写真では, 肺浸潤像が認められ, 肺拡散障害が年齢とともに進行する。眼底のチェリー・レッドスポットは約1/3の患者さんに認められるが, 目立った中枢神経症状はほとんどない。
 C型は, 新生児期の死亡から成人期に発症する患者さんまで幅広い発症年齢と症状がある。新生児発症では, 胎児水腫, 胎児腹水で発症する患者さんもおり, 胆汁うっ滞型横断と肝脾腫を示す患者が多い。肝脾腫, 肺症状などの身体症状は神経症状より早期に出現することが多い。脾腫は年齢とともに目立たなくなる。また, 肝脾腫を認めない患者さんもいる。神経症状は, 小脳失調, 構音障害, 燕下障害, 知的障害, 痙れん, ジストニアなどが進行する。核上性垂直性眼球運動障害とカタプレキシー(笑うと力が抜ける)は本症に特徴的である。成人発症例には精神症状も多い。
診断
 A型, B型では, 骨髄中の泡沫細胞(ニーマンピック細胞)が特徴的で診断に有用。確定診断には, 末梢リンパ球や培養皮膚線維芽細胞の酸性スフィンゴミエリナーゼの酵素活性を測定する。酵素活性が低値(10%以下)の時には, 本症と診断できる。B型の残存酵素活性はA型よりやや高い。遺伝子診断としては, SPD1遺伝子変異を検出する。
 C型断では, 骨髓の泡沫細胞の確認と皮膚線維芽細胞のフィリピン染色による遊離型コレステロールの蓄積を確認することが診断に有用である。遺伝子診断としてはNPC1, NPC2の遺伝子変異を検出する。
診断方法
1. 典型例ではカタレプキシー, 垂直方向の眼球運動障害が見られる。
2. 確定診断は, 骨髄の泡沫細胞の確認と, 末梢血リンパ球または培養線維芽細胞のライソゾーム酵素活性測定, および線維芽細胞のフィリピン染色によるコレステロール蓄積の確認により行われる。
3. 遺伝カウンセリングなどの情報として, 遺伝子診断は有用である。しかし, フィリピン染色などで診断が確実となった患者でも, 遺伝子診断では変異が見つからない場合がある。
当該事業における対象基準
全A  疾患名に該当する場合

治療
A型やB型患者さんには, 骨髄移植が試みられているがA型の神経症状には無効であり, 本治療の有効性に関してのエビデンスは乏しい。現在, B型患者さんに対する酵素補充療法が開発されつつあり, 米国で臨床研究が進められている。
C型では, ガングリオシド合成系の酵素を阻害するMilglustat(ブリーザベス)が治療薬として承認されており, 神経症状にある程度の効果が期待できる。また, シクロデキストリンの髄注による臨床研究が日本でも進められている。

予後
A型は予後不良で, ほとんどの患者さんが3歳前後に死亡する。B型は緩徐進行性の経過をとることが多い。C型では, 新生児発症では予後不良が多く, 低年齢での発症は神経症状の進行が早い。
成人期以降
 B型は成人期以降に肝脾腫などの症状で発症することがあり, 成人においても鑑別診断に入れておく必要がある。C型では, 成人期以降に精神症状で発症する例があり注意を要する。

(責任遺伝子) *607623 NPC intracellular cholesterol transporter 1 (NPC1) <18q11.2>
.0001 Niemann-Pick disease, type C1 (257220) [NPC1, GLN928PRO] (rs28940897) (RCV000003091) (Carstea et al. 1997)
.0002 Niemann-Pick disease, type C1 [NPC1, THR1036MET] (rs28942104) (gnomAD:rs28942104) (RCV000176149...) (Carstea et al. 1997)
.0003 Niemann-Pick disease, type C1 [NPC1, ASN1156SER] (rs28942105) (gnomAD:rs28942105) (RCV000003093) (Carstea et al. 1997)
.0004 Niemann-Pick diseasem type D (257220) [NPC1, GLY992TRP] (rs80358254) (RCV000003094...) (Greer et al. 1997)
.0005 Niemann-Pick disease, type C1 [NPC1, 1553G-A] (rs80358254) (gnomAD:rs80358254) (RCV000723413...) (Yamamoto et al. 1999)
.0006 Niemann-Pick disease, type C1, adult form [NPC1, VAL889MET] (rs120074130) (RCV000003096) (Yamamoto et al. 1999)
.0007 Niemann-Pick disease, type C1, adult form [NPC1, IVS, 1-BP DEL, A, 3043-2] (rs797044431) (RCV000674121...) (Yamamoto et al. 1999)
.0008 Niemann-Pick disease, type C1, juvenile form [NPC1, TYR1088CYS] (rs28942106) (RCV001056811...) (Yamamoto et al. 1999)
.0009 Niemann-Pick disease, type C1, juvenile form [NPC1, LEU1213PHE] (rs120074131) (gnomAD:rs120074131) (RCV000003099) (Yamamoto et al. 1999)
.0010 Niemann-Pick disease, type C1 [NPC1, ILE1061THR] (rs80358259) (gnomAD:rs80358259) (RCV000254672...) (Millat et al. 1999)
.0011 Niemann-Pick disease, variant type C1 [NPC1, ARG958GLN] (rs120074132) (gnomAD:rs120074132) (RCV000003102) (Sun et al. 2001)
.0012 Niemann-Pick disease, variant type C1 [NPC1, PRO1007ALA] (rs80358257) (gnomAD:rs80358257) (RCV000254671...) (Sun et al. 2001; Millat et al. 2001)
.0013 Niemann-Pick disease, type C1 [NPC1, GLY992ARG] (rs80358254) (gnomAD:rs80358254) (RCV000489250...) (Millat et al. 2001)
.0014 Niemann-Pick disease, type C1 [NPC1, VAL378ALA] (rs120074134) (gnomAD:rs120074134) (RCV000003104) (Millat et al. 2001)
.0015 Niemann-Pick disease, type C1 [NPC1, VAL950MET] (rs120074135) (gnomAD:rs120074135) (RCV000003105...) (Millat et al. 2001)
.0016 Niemann-Pick disease, type C1 [NPC1, ALA1035VAL] (rs28942107) (gnomAD:rs28942107) (RCV000003106...) (Ribeiro et al. 2001)
.0017 Niemann-Pick disease, type C1 [NPC1, IVS23, G-A, +1] (rs786200877) (gnomAD:rs786200877) (RCV000003107) (Ribeiro et al. 2001)
.0018 Niemann-Pick disease, type C1 [NPC1, CYS177TYR] (rs80358252) (RCV000623140...) (Ribeiro et al. 2001)
.0019 Niemann-Pick disease, type C1 [NPC1, IVS16, G-A, -82] (RCV000003109) (Ribeiro et al. 2001)
.0020 Niemann-Pick disease, type C1 [NPC1, ARG978CYS] (rs28942108) (gnomAD:rs28942108) (RCV000003110...) (Ribeiro et al. 2001)
.0021 Niemann-Pick disease, type C1 [NPC1, 1-BP DEL, 3662T] (rs786200878) (RCV000003111) (Ribeiro et al. 2001)
.0022 Niemann-Pick disease, type C1 [NPC1, CYS113ARG] (rs120074136) (RCV000003112) (Blom et al. 2003)
.0023 Niemann-Pick disease, type C1 [NPC1, 4-BP DEL, 3611-3614] (rs786200879) (RCV000003113) (Blom et al. 2003)

*NPC1 (NPC Intracellular Cholesterol Transporter 1)
 Genome size 80,434 bp, Minus strand, 1278 aa, 142167 Da
 Exons: 25, Coding exons: 25, Transcript length: 4,760 bps, Translation length: 1,278 residues
●エンドソームとリソソームの境界膜に位置する大きなタンパクをコードする
 →コレステロールがそのN末ドメインと結合することで細胞内コレステロール交通を調停する
 1つの cytoplasmic C-terminus, 13 の transmembrane domains, エンドソーム腔の3つの大きなループをもち,最後のループはN末にある
 後半のエンドソーム/リソソーム区画に LDLを輸送し,水解し, free cholesterolを遊離する
 NPC2とともに作用する細胞内コレステロールトランスポーターで,エンドソーム/リソソーム区画からのコレステロールの出口で重要な役割をもつ
 後半のエンドソーム/リソソーム区画の腔からのLDLsから遊離された非エステル化コレステロールは,NPC2によりNPC1のN末ドメインのコレステロール結合ポケットに移動される
 コレステロールは結合ポケットに埋め込まれたヒドロキシル基でNPC1と結合する
 コレステロールより高い親和性でoxysterolと結合する
 グリアでの小胞交通で役割をもつかも
 ebolavirusのエンドソーム入り口受容体をして作用する
●関係する pathways: Lipoprotein metabolism and Metabolism

(ノート)
A number sign (#) is used with this entry because Niemann-Pick disease type C1 and Niemann-Pick disease type D, also known as the Nova Scotian type, are caused by mutation in the NPC1 gene (607623).

●Niemann-Pick C型 (NPC) 病は, 常染色体劣性の脂質蓄積症で, 進行性神経変性が特徴である
 症例の約95%は NPC1 遺伝子変異が原因で, C1型と呼ばれる
 症例の5%はNPC2 遺伝子 (601015)の変にが原因で, C2型 (607625)と呼ばれる
 C1型とC2型の臨床症状は, 各々の遺伝子が両方とも脂質の退出に関与するので類似する
 →特にコレステロールのエンドソームまたはリソソームからの退出 (Vance, 2006).

●歴史的に Crocker (1961) は4つのタイプの Niemann-Pick 病を分離した
 古典的乳児型 (type A; 257200)
 内臓型 (type B; 607616)
 亜急性または若年型 (type C)
 Nova Scotian バリアント (type D)
  C1 と D 型は, D型が Nova Scotian Acadian を祖先にもつ患者で生じる他は区別できない
 その後 E 型と F 型も記載されている (607616)
 各々のグループ内の表現型の多様性も記載されている

臨床症状
●C型 Niemann-Pick 病の臨床表現型には非常に差異がある
 古典的小児期発症のC型患者は, 1-2年間は通常正常にみえる
 症状は, 2-4歳の間に出現する
 患者は次第に神経学的異常を生じ, 最初は, 運動失調, 大発作てんかん, および以前に習得した発語の喪失をみる
 痙性が顕著で, とくにミオクローヌスけいれんが多い
 その他の特徴には, ジストニア, 垂直核上性注視麻痺, 認知症, 精神症状がある
 一般的には, 肝脾腫が A 型や B 型より目立たないが, 数例では致死的なことがある
 数例では胆汁うっ滞性黄疸が生じる
 独特の組織生化学および電顕像をもつ泡沫 Niemann-Pick 細胞と '海青' 組織球が, 骨髄にみられる
 小児期発症型では, 通常5-15歳で死亡する (Brady, 1983, Patterson et al., 2001)
 成人発症型も報告されており, 徐々に発症し, より緩徐な進行を示す (例, Shulman et al., 1995)

DeLeon et al. (1969) described 2 females and a male in a black kindred with a juvenile form of cerebral lipidosis. Clinical features were onset between age 4 and 9 years, dementia progressing to complete amentia and an akinetic mute state, grand mal and minor motor seizures, progressive dystonia of posture with tendency to flexion of the arms, hyperextension of the spine and extension of the legs, clumsiness and mild atypical ataxia, some intention tremor and athetosis, grasp reflexes and severe reflex trismus in the final stages, tendency to hyperreflexia but preservation of fair strength and normal plantar reflexes until late. Notably absent were retinal degeneration, myoclonus, prominent pyramidal or bulbar involvement, and hepatosplenomegaly. In 1 case, foam histiocytes were demonstrated in the bone marrow. Cerebral sphingolipids in biopsy-obtained material were normal. Electron microscopic findings by Elfenbein (1968) supported the distinctness of this entity, which they called 'dystonic juvenile idiocy without amaurosis'. The cases reported by Kidd (1967) as 'atypical cerebral lipidosis', and Karpati et al. (1977) as 'juvenile dystonic lipidosis', are thought to be identical.

Neville et al. (1973) found 3 pairs of affected sibs and an equal sex incidence. Two brothers were reported by Grover and Naiman (1971). Neurologic manifestations included vertical gaze paresis and progressive dysarthria.

A variant of Niemann-Pick disease, most likely type C, was observed in 9 children in 5 families by Wenger et al. (1977). Neonatal jaundice, easy bruisability, vertical supranuclear ophthalmoplegia, intellectual and neurologic deterioration, hepatosplenomegaly, and sea-blue or foamy histiocytes were features. All 5 families were from the old Spanish-American population of southern Colorado or New Mexico. Low (average about 30% of normal) activity of sphingomyelinase was found in the fibroblasts of 7 of 8 cases evaluated. A similar case was reported in a Spanish woman from northern New Mexico by Kornfeld et al. (1975).

The patient reported by Longstreth et al. (1982) as 'adult dystonic lipidosis' may have had this disorder: a 43-year-old man who presented with splenomegaly and a 20-year history of a neurologic disorder that included vertical supranuclear ophthalmoplegia, mild dementia, and a movement disorder. Adult dystonic lipidosis was diagnosed from the clinical picture and demonstration of foamy and sea-blue histiocytes in bone marrow. Niemann-Pick disease was excluded by normal sphingomyelinase activity in cultured skin fibroblasts. The patient, who also had mitral valve prolapse, was able to work as a janitor until age 37 years. Lysosomal storage of neutral fat and phospholipids was suggested by electron microscopy.

In ocular histopathologic studies of a girl who died at age 11 years, Palmer et al. (1985) noted lipid deposits.

Witzleben et al. (1986) emphasized that childhood cirrhosis is a feature of NPC. They reported 2 unrelated cases. Skin fibroblasts in one showed sphingomyelinase activity that was 42% of control values. The hepatic storage underlying the cirrhosis was typically inconspicuous; however, sea-blue histiocytes in the marrow could be considered a valuable diagnostic clue.

In a collaborative study in Lyon, France, Denver, Colorado, and Bethesda, Maryland, Vanier et al. (1988) studied 70 patients with type C Niemann-Pick disease clinically and biochemically. Age of onset ranged from the neonatal period to 55 years. More than 90% of the patients had some degree of splenomegaly and/or hepatomegaly, but notably, some had none. Neurologic deterioration was a central characteristic of the disease, but onset and progression varied. In infancy, there was hypotonia, developmental delay, mental deterioration, and spasticity. In childhood, there was cerebellar ataxia, poor school performance, dysarthria, dystonia, vertical supranuclear gaze palsy, and seizures. Two patients had adult-onset disease with neurologic and psychiatric manifestations. Bone marrow biopsies consistently showed foam cells and/or sea-blue histiocytes. Sphingomyelinase activity was normal or somewhat reduced (47% of controls). Very low cholesterol esterification rates were observed in more than 90% of the patients, including all cases with the most severe forms of the disease.

On the basis of the analysis of 22 patients, Fink et al. (1989) delineated 3 phenotypes of NPC: (1) an early-onset, rapidly progressive form associated with severe hepatic dysfunction and psychomotor delay during infancy and later with supranuclear vertical gaze paresis, ataxia, marked spasticity, and dementia; (2) a delayed-onset, slowly progressive form heralded by the appearance, usually in early childhood, of mild intellectual impairment, supranuclear vertical gaze paresis, and ataxia, and later associated with dementia and, variably, seizures and extrapyramidal deficits; and (3) a late-onset, slowly progressive form distinguished from the second pattern by later age of onset (adolescence or adulthood) and a much slower rate of progression. Phenotypes 1 and 2 have been observed in the same sibship. Omura et al. (1989) reported 6 cases.

Turpin et al. (1991) discussed the form of type C Niemann-Pick disease that starts in adolescence or adulthood and shows a slower evolution than does the infantile form. Psychomotor retardation is a consistent feature. Cerebellar ataxia and extrapyramidal manifestations are often found rather than pyramidal manifestations. Supranuclear ophthalmoplegia with paralysis of down-gaze is nearly constant. Cataplexy and other types of seizures may be found during the evolution of the disease. In some cases a psychosis may be the only manifestation for several years; the treatment by psychotropic drugs raises the question of a superimposition of a drug-induced lipidosis. Although hepatosplenomegaly is a consistent finding in children in the infantile form of the disease, hepatomegaly is often absent in the adult forms and splenomegaly, although generally present, is not pronounced. Foam cells or sea-blue histiocytes are found on bone marrow biopsy.

Imrie et al. (2002) reported 17 patients with Niemann-Pick type disease type C who presented in late childhood or adulthood. They suggested that adult patients are often referred to clinicians with psychosis or other major psychiatric problems. The dystonia with preserved intellectual functioning can be mistaken for other basal ganglia disorders such as Wilson disease (277900). The presence of vertical gaze palsy is an important clinical clue and, in the presence of a modest increase in plasma chitotriosidase activity, can be helpful in the differential diagnosis. Imrie et al. (2002) concluded that the diagnosis should be confirmed in suspected cases by filipin staining of cultured fibroblasts, as well as cholesterol esterification studies and DNA mutation analysis. They stated that in most adult-onset patients the presenting neurologic abnormality will be a combination of ataxia and dysarthria. As the disease progresses, dystonia and seizures may occur. The characteristic ocular abnormality (supranuclear gaze palsy) usually appears early in the course of the disease but can be very subtle initially and only detected by detailed ophthalmologic assessment. In 3 patients, symptoms of the disease appeared with or were exacerbated by pregnancy.

Josephs et al. (2004) reported a 75-year-old woman who was a heterozygous carrier of an NPC1 mutation (607623.0013). She presented with a 10-year history of tremor, initially a side-to-side head tremor, which later progressed to her upper extremities. The tremor was worse at rest and worsened with mental activity, and she was initially diagnosed with Parkinson disease (168600). The patient had 3 brothers who were affected by a severe childhood-onset neurologic disorder characterized by spastic dysarthria, tremor, paresis of vertical eye movements, disturbance of gait, and splenomegaly (Willvonseder et al., 1973). Josephs et al. (2004) concluded that their patient was a manifesting carrier of Niemann-Pick disease type C and that her brothers likely carried 2 mutations in the NPC1 gene.

Garver et al. (2007) analyzed data from 87 questionnaires received from Niemann-Pick type C1 families living in the United States and reported that the average age of diagnosis was 10.4 years, with one-half of patients being diagnosed before the age of 6.9 years, and the average age of death was 16.2 years, with one-half of all patients dying before the age of 12.5 years. The most common clinical symptom reported at birth was neonatal jaundice (52%), followed by enlargement of the spleen (36%) and liver (31%); ascites (19%) and neonatal hypotonia (6%) were much less frequent. Common developmental difficulties included clumsiness (87%), learning difficulties (87%), ataxia (83%), dysphagia (80%), and vertical gaze palsy (81%). The questionnaires formed the basis for the National NPC1 Disease Database.

In a study of ocular movements of 3 adult patients with biochemically confirmed NPC disease, Abel et al. (2009) found that reflexive saccade latency ranged from shorter to longer than normal, reflexive saccade gain was reduced, asymptotic peak velocity was reduced, fewer self-paced saccades were generated, and increased errors on antisaccades were made by patients compared to controls. Patients with more severe biochemical, cognitive, and symptom deficits performed most poorly on brainstem and frontal ocular motor measures. Paradoxically, less severe illness was associated with an abnormally reduced saccadic latency. The findings suggested that reduced saccadic latency may result from inadequate fixation input from abnormally functioning frontal eye fields. All patients had presented with a psychotic illness. Abel et al. (2009) concluded that ocular motor measures may provide an index of disease severity in Niemann-Pick disease type C, and may be a useful adjunct for monitoring disease progression and medication response.

Walterfang et al. (2010) reported the neuroradiologic findings of 6 patients with adult-onset NPC who presented with psychosis, ophthalmoplegia, or a dysexecutive syndrome. Compared to controls, patients had bilateral focal gray matter reductions in the hippocampus, thalamus, superior cerebellum, and insula, in addition to smaller regions of the inferoposterior cortex. These changes corresponded to the clinical findings in adults, although the frontal cortex did not show changes on imaging. Fractional anisotropy showed widespread reductions in major white matter tracts affecting most brain regions, which appeared to be due to both impaired myelination and altered axonal structure. Overall, the findings were consistent with a selective vulnerability of certain neuronal populations; the more widespread white matter changes were consistent with the hypothesis that disrupted myelination and axonal structure may predate changes to the neuronal cell body.

Fetal Niemann-Pick Disease Type C
Spiegel et al. (2009) reported 7 patients from 5 unrelated families with fetal onset of NPC. Three of the families were consanguineous: 2 of Arab Muslim descent and 1 of Ashkenazi Jewish descent. Two fetuses were diagnosed prenatally based on the combination of splenomegaly and ascites early in the third trimester, followed by analysis of cultured amniocytes. Three patients were diagnosed postnatally, and the last 2 were diagnosed based on an affected sib. The prognosis was very poor in all patients: 1 died in utero, 1 pregnancy was terminated, and 4 died within the first 7 months of life from neonatal cholestatic disease. The seventh patient had developmental regression at age 10 months, followed by rapid neurologic deterioration with spastic quadriplegia, profound mental retardation, seizures, and generalized white matter dysmyelination. The fetal presentations included in utero splenomegaly (6 of 7), in utero hepatomegaly (5 of 7), in utero ascites (4 of 7), intrauterine growth retardation (2 of 7), and oligohydramnios (2 of 7). Placentomegaly and intervillous thrombosis was present in 2 of 3 pregnancies examined. Congenital thrombocytopenia (4 of 4), congenital anemia (2 of 4), and petechial rash (2 of 5) were diagnosed immediately after birth in some. Genetic analysis confirmed the diagnosis in all cases. Spiegel et al. (2009) suggested that fetal onset may represent a unique subset of neonatal NPC with a grave prognosis.

Niemann-Pick Disease, Type D (Nova Scotian)
Although Niemann-Pick disease type C and type D are clinically similar, Greer et al. (1997) suggested that NPD has a more homogeneous expression than NPC and that patients with NPD resemble less severely affected NPC patients.

Studying a 13-year-old Nova Scotian case, Rao and Spence (1977) found elevated sphingomyelin, especially in the spleen, and even greater elevation of free cholesterol. They could not demonstrate deficiency of total sphingomyelinase.

Jan and Camfield (1998) performed a retrospective clinical study of 20 cases of Nova Scotian NPD. The female-to-male ratio was 2 to 1. Five of the children had severe neonatal jaundice. Early milestones were normal in the majority. Neurologic symptoms developed between 5 and 10 years of age, with a mean age at diagnosis of 7.2 years. Seizures developed in all children between 4.5 and 16 years of age and were followed by significant physical and mental deterioration. Age at death was between 11 and 22.5 years, with the majority dying of pneumonia.

Inheritance
Niemann-Pick disease type C is an autosomal recessive disorder (Vanier and Millat, 2003).

Inheritance of Type D
Winsor and Welch (1978) gave a full genetic discussion of the Nova Scotian or type D Niemann-Pick disease. They identified 19 cases distributed in 15 sibships, in French Acadians of Yarmouth County, N.S. All 30 parents traced back to Joseph Muise, married to Marie Amirault, who lived in the late 1600s and early 1700s. Two other common ancestral couples were identified, but the Muise-Amirault couple had by far the largest number of 'valid coincidences.' (Since all forebears of a common ancestor appear on both sides of the pedigree, not every match will indicate a 'real' common ancestor, which occurs when the common ancestor's child on the father's side is different on the mother's side. Mange (1964) termed the latter situation a 'valid coincidence.') Carrier frequency was presumably high, because none of the affected sibships had closely related parents and because a considerable proportion of children chosen at random could be traced to the Muise couple. Fredrickson and Sloan (1972) described 3 sibs with a disorder clinically identical to the Nova Scotian disorder. The father could be traced to the Muise couple; the mother was Italian. Winsor and Welch (1978) suggested these children might have a genetic compound disorder, the Acadian mutation being unique.

Diagnosis
Argoff et al. (1990) suggested that assay for the deficiency, which shows impaired ability of cultured fibroblasts to esterify exogenously supplied cholesterol, is useful for confirming the diagnosis in patients with atypical presentation. Boustany et al. (1990) a suggested that characteristic ultrastructural changes may be useful to the diagnosis.

Vanier et al. (1991) reported on a personal experience with 134 cases, which indicated that the diagnosis is best reached by the combined demonstration of a deficient induction of esterification of cholesterol and of an intravesicular cholesterol storage by cytochemistry after filipin staining. They gave brief reports of 6 adult-onset cases. Although there was a wide phenotypic spectrum, complementation studies yielded no evidence of separate complementation groups.

Ceuterick and Martin (1994) demonstrated osmiophilic pleomorphic lamellar inclusions in dermal fibroblasts and perivascular histiocytes in skin biopsies in 8 Niemann-Pick type C patients but not in 473 controls. They emphasized that a skin biopsy may be useful diagnostically.

Imrie and Wraith (2001) described 4 patients with Niemann-Pick disease type C in whom the presentation was isolated splenic enlargement; this remained the only abnormality for a number of years. They stated that the diagnosis can be suggested by either finding abnormal storage material in a tissue biopsy specimen or by showing a modest elevation in plasma chitotriosidase activity. In patients with suggestive abnormalities, filipin staining of a skin fibroblast sample should confirm the abnormality in cholesterol trafficking. They suggested that formal esterification studies and mutation analysis should be performed, especially if prenatal testing is to be done in subsequent pregnancies. If the diagnosis is not considered and established, the family is at risk of having further affected children.

The biochemical diagnosis of NPC relies on the use of patient skin fibroblasts in an assay to demonstrate delayed low-density lipoprotein (LDL)-derived cholesterol esterification and a cytologic technique (filipin staining) to demonstrate the intracellular accumulation of cholesterol. A few patients, referred to as 'NPC variants,' present with clinical symptoms of NPC but show near-normal results of these biochemical tests. Sun et al. (2001) demonstrated that NPC-variant fibroblast samples can be detected as sphingolipid storage disease cells by using a fluorescent sphingolipid analog that accumulates in endosomes/lysosomes in variant cells preincubated with LDL cholesterol but targeted to the Golgi complex in normal cells under these conditions.

Sidhu et al. (2020) developed and validated a mass spectrometry method to measure N-palmitoyl-O-phosphocholineserine (PPCS), a lipid found to be elevated in NPC1, in biomaterials including plasma, serum, and cerebrospinal fluid (CSF). At a cutoff of 248 ng/mL in plasma, PPCS has 100% specificity and 96.6% specificity in differentiating NPC1 patients from controls and NPC1 carriers, respectively. Sidhu et al. (2020) also found that elevation of PPCS in CSF from patients with NPC1 correlates with NPC neurologic disease severity scores. In a clinical trial with intravenous 2-hydroxypropyl-beta-cyclodextrin, plasma PPCS was significantly reduced, thus demonstrating that this biomarker can be used to evaluate the peripheral treatment efficacy of intravenous 2-hydroxypropyl-beta-cyclodextrin.

Mapping
The locus corresponding to the mouse NPC phenotype (Pentchev et al., 1984), symbolized spm, was shown by Sakai et al. (1991) to be on mouse chromosome 18. Since mouse chromosome 18 has extensive syntenic homology with human chromosomes 5 and 18, Carstea et al. (1993) undertook linkage analysis with markers specific to these chromosomes. No linkage was found with chromosome 5, but strong evidence of linkage was found with chromosome 18. Within affected offspring, the chromosome 18 parental contribution was identical, as demonstrated by allele-specific microsatellite markers. Significant linkage of NPC to an 18p genomic marker, D18S40, was indicated by a 2-point lod score of 3.84. Three recombinants detected among the 28 informative individuals represented a recombination fraction of 0.07. Analysis of meiotic chromosomal breakpoint patterns among the affected individuals indicated that the NPC gene is located in the pericentromeric region of chromosome 18, probably on the short arm. In their Figure 2, Carstea et al. (1993) demonstrated how chromosome 18 was divided into 6 regions, designated A through F, and how meiotic recombination resulted in divergent segregation of one or more markers and the NPC phenotype. Only 1 of the 6 intervals, a pericentromeric one, showed no evidence of meiotic recombination. By linkage studies, Carstea et al. (1994) located the NPC gene to a region defined by DNA markers in the 18q11-q12 region. In 1 family linkage to this region was excluded, suggesting the existence of a separate gene that codes for an additional component required for intracellular movement of cholesterol (see below).

Greer et al. (1997) presented linkage evidence supporting allelism of NPC and NPD. They found that NPD in Nova Scotia is tightly linked (recombination fraction = 0.00; maximum lod score = 4.50) to a microsatellite marker, D18S480, from the centromeric region of 18q. This is the same site as that to which the NPC1 gene (607623) was mapped by Carstea et al. (1994). In a study of a single large kindred with NPD, Greer et al. (1999) used linkage disequilibrium mapping and 5 newly developed polymorphic microsatellite markers to narrow the NPC1 critical region to a 5-cM interval.

Heterogeneity
Genetic Heterogeneity
To investigate the possibility that mutation at more than one locus can cause the disorder, Steinberg et al. (1994) undertook somatic cell hybridization experiments using skin fibroblast strains from 12 patients representing a wide clinical spectrum. Using filipin staining of free cholesterol as a marker for complementation, they found evidence for the existence of 1 major group, called group alpha, and a minor group, called group beta, represented by 1 mutant strain. Other experiments in which sphingomyelinase activity was measured as a marker for complementation using 5 mutant strains showed activity consistently less than 40% of control levels, confirming the existence of the second group, later termed NPC2. Further support for the genetic heterogeneity was provided by Vanier et al. (1996) from complementation studies by somatic cell hybridization and linkage analysis. Crosses between various cell lines revealed a major complementation group (type C1) comprising 27 unrelated patients and a second minor group (type C2) comprising 5 patients. Linkage analysis in a multiplex family belonging to the minor complementation group showed that the mutated gene did not map to 18q11-q12 where the major gene is located. Patients in the first group spanned the whole spectrum of clinical and cellular phenotypes. No consistent clinical or biochemical phenotype was associated with the second complementation group; however, 3 of the 5 patients in group 2 presented with severe pulmonary involvement leading to death with the first year of life (see NPC2; 607625). The causative NPC2 gene was later identified (see 601015).

Vanier and Millat (2003) stated that approximately 95% of patients with Niemann-Pick disease type C have mutations in the NPC1 gene, which encodes a large membrane glycoprotein primarily located to late endosomes, and the remainder have mutations in the NPC2 gene, which encodes a small soluble lysosomal protein with cholesterol-binding properties. The identical biochemical patterns observed in NPC1 and NPC2 mutants suggested that the 2 proteins function in a coordinate fashion. The NPC1 and NPC2 proteins are involved in the cellular postlysosomal/late endosomal transport of cholesterol, glycolipids, and other cargo.

Pathogenesis
Brady (1978) pointed out that sphingomyelinase is deficient in type C as well as in types A and B. Although he stated that total sphingomyelinase activity may be 'attenuated' in some patients with types D and E, he raised doubts about the classification of type D as a sphingomyelin storage disease.

On the basis of somatic cell hybridization studies, Besley et al. (1980) suggested that types A and B may be genetically distinct from type C. Fusion of type C cells with either type A or type B cells resulted in restoration of sphingomyelinase activity.

Gilbert et al. (1981) reported extensively on the cases of 2 sisters who died at ages 8 and 7 years of the progressive CNS degenerative process of Niemann-Pick disease type C. Biochemical analyses showed elevated levels of sphingomyelin in liver and spleen with normal total sphingomyelinase activity. However, by isoelectric focusing, sphingomyelinase activity in the range of pI 4.6-5.2 was markedly reduced, whereas normal amounts of more acidic components were found. A similar explanation for 'Niemann-Pick disease without sphingomyelinase deficiency' may obtain in other cases.

Pentchev et al. (1985) were prompted to study cholesterol esterification in Niemann-Pick disease because of the similar phenotypic findings in a murine mutation affecting cholesterol esterification (Pentchev et al., 1984). They found esterification to be normal in 6 type A and 8 type B Niemann-Pick cell lines. In striking contrast, all 24 type C Niemann-Pick cell lines showed a major block in cholesterol esterification, whereas internalization and lysosomal processing of lipoprotein cholesterol was apparently normal. Acyl-CoA:cholesterol acyltransferase activity was also normal in type C cell extracts. Fluorescent microscopy showed that type C cells grown in fetal calf serum stored much unesterified cholesterol. The partial expression of the esterification defect (50% of normal) in heterozygous mice indicated that it is the primary fault.

Kruth et al. (1986) and Pentchev et al. (1986) discussed the abnormality of cholesterol metabolism in this disorder. In both heterozygous and homozygous type C Niemann-Pick fibroblasts, excessive uptake of LDL cholesterol and deficient esterification of the internalized cholesterol were observed. As reported by Pentchev et al. (1985), Liscum and Faust (1987) found that LDL does not stimulate cholesterol esterification in this disorder; however, they also showed that LDL does not down-regulate cholesterol synthesis or LDL receptor activity normally. They suggested that the intracellular processing of LDL-derived cholesterol may be defective in NPC fibroblasts. This suggestion was corroborated by the findings of Sokol et al. (1988), who examined the intracellular accumulation of unesterified cholesterol in normal and Niemann-Pick C fibroblasts. They found that the plasma membrane cholesterol of normal cells was more readily replenished by internalized LDL cholesterol than that of mutant fibroblasts. Their studies suggested that deficient translocation of exogenously derived cholesterol from lysosomes to other intracellular membrane sites may have an important pathophysiologic role in type C Niemann-Pick disease.

Vanier et al. (1988) demonstrated that cultured homozygous NPC cells challenged with pure human low-density lipoproteins showed a pronounced deficiency in cholesterol esterification and that heterozygotes showed intermediate rates of esterification. All other pathologic conditions studied, including types A and B Niemann-Pick disease, gave normal results. There appeared to be a correlation between the clinical phenotype and severity of the biochemical lesion.

Blanchette-Mackie et al. (1988) showed that incubation of fibroblasts from patients with type C Niemann-Pick disease with low density lipoprotein resulted in excessive intracellular accumulation of unesterified cholesterol not only in lysosomes but also at an early stage in the Golgi complex. They suggested that the Golgi complex may play a role in the intracellular translocation of exogenously derived cholesterol and that disruptions of the cholesterol transport pathway at the Golgi may, in part, be responsible for the deficiency in cholesterol utilization in this disorder.

Thomas et al. (1989) found that the sphingomyelinase deficiency (37.9% of normal on the average) could be corrected in fibroblasts from Niemann-Pick type C patients by removal of the lipoprotein fraction from the culture medium. This is consistent with the view that the primary defect is one affecting the cellular transport and/or processing of free cholesterol and that it is the intracellular storage of cholesterol that causes a marked attenuation of lysosomal sphingomyelinase activity.

Although some biochemical differences may exist between type C and type D Niemann-Pick disease, both show evidence of defective regulation of intracellular cholesterol esterification and storage. Complementation of cholesterol esterification was not observed either when NPC and NPD fibroblasts were fused with polyethylene glycol (Sidhu et al., 1993) or when activity was measured directly in mixed-cell homogenates (Byers et al., 1989).

Roff et al. (1991) pointed out that a number of hydrophobic amines such as imipramine inhibit low-density lipoprotein-induced esterification of cholesterol and cause unesterified cholesterol to accumulate in perinuclear vesicles. When stained with filipin, the appearance is indistinguishable from that seen in NPC fibroblasts. Thus, these agents produce a cholesterol lipidosis similar to that of NPC, which is due to defective post-lysosomal cholesterol transport. Roff et al. (1991) raised the possibility that an endogenous hydrophobic amine such as sphinganine may inhibit cholesterol transport in NPC.

Nerve cells demonstrate not only storage of cholesterol but also neurofibrillary tangles containing paired helical filaments, similar to the neurofibrillary tangles present in Alzheimer disease (see 104300), Kufs disease (see 204300), Down syndrome (190685), tuberous sclerosis (see 191100), progressive supranuclear palsy (601104), and neurodegeneration with brain iron accumulation-1 (NBIA1; 234200), among others. The presence of neurofibrillary tangles in Niemann-Pick type C distinguishes it from other types of Niemann-Pick disease. Auer et al. (1995) demonstrated tau protein (157140) in Western blots from brain tissue in 5 cases of Niemann-Pick type C.

In 3 patients in their thirties with genetically confirmed Niemann-Pick disease type C who were homozygous for the APOE4 (107741) allele, Saito et al. (2002) found abundant neurofibrillary tangles, widespread increased beta-amyloid diffuse plaques, and severe tau pathology. The authors suggested that NPC1 gene mutations combined with homozygosity of APOE4 alleles leads to pathology similar to that found in Alzheimer disease.

Vance (2006) provided a detailed review of the cellular mechanisms of lipid imbalance in NPC. Accumulation of cholesterol and gangliosides disrupts intracellular trafficking and affects normal cholesterol use within the cell.

Lloyd-Evans et al. (2008) found that lysosomal sphingosine storage and reduced lysosomal calcium levels were early events in development of the NPC phenotype in normal human cells exposed to the NPC-inducing drug U18666A. In this model, accumulation of cholesterol, sphingomyelin, and glycerosphingolipid was a secondary event. Pharmacologic elevation of cytosolic calcium or reduction of sphingosine content reversed the NPC phenotype in several cellular models of NPC, and sphingosine alone induced the abnormal calcium phenotype in a concentration-dependent manner. Treatment of Npc1 -/- mice with curcumin, a weak SERCA (see 108730) antagonist that elevates cytosolic calcium levels, increased life expectancy by 35% and slowed the rate of disease progression by 3 weeks. Lloyd-Evans et al. (2008) concluded that NPC1 is involved in sphingosine efflux from lysosomes, and that lysosomal sphingosine accumulation in NPC alters intracellular calcium concentration and causes abnormal endocytic trafficking.

Molecular Genetics
In several patients with Niemann-Pick disease type C, Carstea et al. (1997) identified mutations in the NPC1 gene (607623.0001-607623.0003). In a study of cDNA and genomic DNA isolated from the fibroblasts of 11 patients with NPC1, 10 Japanese (7 late infantile, 2 juvenile, and 1 adult form of the disease) and 1 Caucasian, Yamamoto et al. (1999) found 14 novel mutations in the NPC1 gene, including small deletions and point mutations.

Yamamoto et al. (2000) studied 15 Japanese and 2 white patients with NPC. They found that in those patients with the late infantile form of the disease, there was a clear reduction of the NPC1 protein level regardless of the type of mutation, and 5 fibroblast lines expressed undetectable levels of NPC1 protein. Patients with a late clinical onset were distinct in that all of their skin fibroblasts expressed considerable levels of mutant NPC1 protein.

In the Nova Scotian variant of Niemann-Pick disease, Greer et al. (1998) demonstrated a 3097G-T transversion in the NPC1 gene, resulting in a gly992-to-trp amino acid substitution (607623.0004).

Kaminski et al. (2002) analyzed the NPC1 gene in 5 German patients with NPC1-related families. They identified a total of 5 novel mutations in the coding region of NPC1.

Population Genetics
Greer et al. (1997) noted that Yarmouth County in Nova Scotia appears to have the world's highest incidence of Niemann-Pick type II disease (encompassing types C and D). The frequency of affected children in 1 region of the county was said to be about 1% and the frequency of heterozygous carriers was estimated to be 10 to 26% (Winsor and Welch, 1978).

To determine the incidence rate of NPC1 and NPC2 (607625), Wassif et al. (2016) analyzed 4 large independent massively parallel exome sequencing projects containing a total 17,754 chromosomes in which no patient had been screened for the diagnosis of Niemann-Pick disease, and analyzed every variant for pathogenicity. The data suggested an incidence rate for NPC1 of 1 in 92,104 and for NPC2 of 1 in 2,858,998. Evaluation of common NPC1 variants, however, suggested that there may be a late-onset NPC1 phenotype with a markedly higher incidence, on the order of 1 in 19,000 to 1 in 36,000. Wassif et al. (2016) determined a combined incidence of classical NPC of 1 in 89,229, or 1.12 affected patients per 100,000 conceptions, but predicted incomplete ascertainment of a late-onset phenotype of NPC1.

Nomenclature
Niemann Pick disease has been classified by some into type I and type II: type I encompasses 2 subtypes, A and B (607616), which show deficiency of sphingomyelinase, and type II encompasses 2 subtypes, type C (NPC1; 257220, NPC2; 607625) and type D (Greer et al., 1997).

History
Christomanou (1980) reported that some patients with the juvenile form of Niemann-Pick disease may be missing a required activator protein. With the fifth edition of The Metabolic Basis of Inherited Disease, types A, B, and C were said to 'appear to be allelic disorders in which 1 of at least 3 different mutations affects the activity of sphingomyelinase' (Brady, 1983). Subsequently, type C proved to be due to mutation in a different gene on a different chromosome from that mutant in types A and B.

Animal Model
Two independently derived mutant mouse colonies played a pivotal role in delineating the biochemical basis of NPC. One was a BALB/c mouse presenting clinical and biochemical features of NPC (Pentchev et al., 1984); the other was the C57BL/Ks mouse characterized as a sphingomyelinosis because of attenuated sphingomyelinase activity and excess sphingomyelin accumulation (Miyawaki et al., 1986; Kitagawa, 1987).

Pentchev et al. (1986) reviewed the findings in the murine disorder and in type C Niemann-Pick disease. The esterification defect concerns exogenously derived cholesterol; synthesis of cholesteryl ester from labeled mevalonic acid and squalene was normal in affected fibroblasts as was endogenous cholesteryl ester synthesis from endogenous cholesterol induced by 25-hydroxycholesterol.

Lowenthal et al. (1990) described Niemann-Pick disease type C in a domestic short-hair kitten. The dam and littermates were donated to Colorado State University, and a breeding colony was established. Brown et al. (1994) reported on the clinical, biochemical, and morphologic findings in 26 affected cats.

Akaboshi et al. (1997) reported that a cell line derived from the C57BL/KsJ mouse model of NPC shows biochemical abnormalities similar to those in fibroblasts derived from human patients. Somatic cell hybridization analysis of these cells and 5 fibroblast strains derived from NPC patients (4 childhood cases and 1 adult case) was carried out. The criterion for complementation was the restoration of the normal intracellular fluorescent pattern in multinucleated cells stained with filipin to demonstrate cholesterol accumulation. These cells could be assigned to 2 complementation groups. The mutant mouse cells did not complement cell strains derived from childhood-type NPC, while they complemented a cell strain derived from an adult patient. The results indicated that the mouse is an authentic model of a major complementation group of NPC, and that NPC consists of genetically heterogeneous groups.

Studying the mutant BALB/c mouse model of NPC, Schedin et al. (1997) investigated enzymatic markers for lysosomes, mitochondria, microsomes, and peroxisomes in liver and brain. In addition to the lysosomal changes, they found a sizable decrease of peroxisomal beta-oxidation of fatty acids and catalase activity in these 2 organs. Isolated peroxisomes displayed a significant decrease in these enzyme activities. Furthermore, the only phospholipid change in brain was a decreased content of the plasmalogen form of phosphatidylethanolamine, and the dimethylacetal pattern was also modified. The electron microscopic appearance of peroxisomes did not show any large changes. The defect of peroxisomal enzymes was already present 18 days before the onset of the disease. In contrast, the lysosomal marker enzyme increased in activity only 6 days after the appearance of the symptoms. The events of the pathologic process had previously been considered to be elicited by lysosomal deficiency, but this study showed disturbances similar to those in a number of peroxisomal diseases. The peroxisomal impairment appeared to be an early event in the process and could be a factor in the development of Niemann-Pick type C disease.

Xie et al. (1999) used the NPC mouse to determine whether the accumulation of unesterified cholesterol in this disorder represents sterol carried in low density lipoprotein (LDL) and chylomicrons (CMs) taken up into the tissues through the coated-pit pathway. A series of observations strongly supported the conclusion that, in Niemann-Pick disease type C, it is the cholesterol carried in LDL and CMs that is sequestered in the tissues, and not sterol that is newly synthesized and carried in high density lipoprotein.

Erickson et al. (2000) used a mouse model with a disrupted Npc1 gene to study 2 cholesterol-lowering drugs (nifedipine and probucol) and the effects of introducing a null mutation in the low density lipoprotein receptor (LDLR; 606945). Although these treatments significantly ameliorated liver cholesterol storage, there was little effect on the onset of neurologic symptoms.

Liu et al. (2000) determined the relative contribution of ganglioside accumulation in the neuropathogenesis of NPC by breeding NPC model mice with mice carrying a targeted mutation in GalNAc-T (601873), the gene encoding the beta-1-4GalNAc transferase responsible for the synthesis of GM2 and complex gangliosides. Unlike the NPC model mice, the double mutant mice did not exhibit central nervous system (CNS) accumulation of gangliosides GM2 or of glycolipids GA1 and GA2. Histologic analysis revealed that the characteristic neuronal storage pathology of NPC disease was substantially reduced in the double mutant mice. By contrast, visceral pathology was similar in the NPC and double mutant mice. Most notably, the clinical phenotype of the double mutant mice, in the absence of CNS ganglioside accumulation and associated neuronal pathology, did not improve. The authors concluded that complex ganglioside storage, while responsible for much of the neuronal pathology, did not significantly influence the clinical phenotype of the NPC model.

Langmade et al. (2006) noted that the failure to properly traffic lipoprotein cholesterol in NPC1 results in impaired oxysterol and steroid synthesis. Langmade et al. (2006) found that treatment of Npc1 -/- mice with the neurosteroid allopregnanolone and a synthetic oxysterol ligand delayed the onset of neurologic symptoms and prolonged life span, suggesting that the treatment bypassed the cholesterol trafficking defect. The therapy preserved Purkinje cells, suppressed cerebellar expression of microglial-associated genes, and reduced infiltration of microglia in cerebellar tissue. Transfection assays correlated the efficacy of treatment with activation of murine PXR (NR1I2; 603065) in vivo.

Elrick et al. (2010) generated Npc1 conditional null mutant mice. Deletion of Npc1 in mature cerebellar Purkinje cells led to an age-dependent impairment in motor tasks, including rotarod and balance beam performance. These mice did not show the early death or weight loss characteristic of global Npc1-null mice, suggesting that Purkinje cell degeneration may not underlie these phenotypes. Histologic examination revealed the progressive loss of Purkinje cells in an anterior-to-posterior gradient. This cell-autonomous neurodegeneration occurred in a spatiotemporal pattern similar to that of global knockout mice. A subpopulation of Purkinje cells in the posterior cerebellum exhibited marked resistance to cell death despite Npc1 deletion. Purkinje cells in both vulnerable and resistant subpopulations displayed no electrophysiologic abnormalities prior to degeneration. The authors concluded that Npc1 deficiency leads to cell-autonomous, selective neurodegeneration and suggested that the ataxic symptoms of NPC disease may arise from Purkinje cell death rather than cellular dysfunction.

(文献)
(1) Besley GTN et al. Somatic cell hybridisation studies showing different gene mutations in Niemann-Pick variants. Hum Genet 54: 409-412, 1980
(2) Christomanou H. Niemann-Pick disease, type C: evidence for the deficiency of an activating factor stimulating sphingomyelin and glucocerebroside degradation. Hoppe Seylers Z Physiol Chem 361: 1489-1502, 1980
(3) Cluistomanou H: Hoppe-Seyler's Z Physiol Chem 361: 1489-1502, 1980
(4) Gilbert EF et al. Niemann-Pick disease type C: pathological, histochemical, ultrastructural and biochemical studies. Europ J Pediat 136: 263-274, 1981
(5) Brady RO: Sphingomyelin lipidoses: Niemann-Pick disease. In Stanbury JB et al. (eds.): The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, Pp. 731, 1983
(6) Pentchev PG et al. A genetic storage disorder in BALB/C mice with a metabolic block in esterification of exogenous cholesterol. J Biol Chem 259: 5784-5791, 1984
(7) Palmer M et al. Niemann-Pick disease--type C: ocular histopathologic and electron microscopic studies. Arch Ophthal 103: 817-822, 1985
(8) Pentchev PG et al. A defect in cholesterol esterification in Niemann-Pick disease (type C): atients. Proc Nat Acad Sci 82: 8247-8251, 1985
(9) Pentchev PG et al. Type C Niemann-Pick disease: a defect in intracellular esterification. Am J Hum Genet 37: A15, 1985
(10) Kruth HS et al. Type C Niemann-Pick disease: abnormal metabolism of low density lipoprotein in homozygous and heterozygous fibroblasts. J Biol Chem 261: 16769-16774, 1986
(11) Miyawaki S et al. A mouse model for Niemann-Pick disease: influence of genetic background on disease expression in spm/spm mice. J Hered. 77: 379-384, 1986
(12) Pentchev PG et al. The cholesterol storage disorder of the mutant BALB/c mouse: a primary genetic lesion closely linked to defective esterification of exogenously derived cholesterol and its relationship to human type C Niemann-Pick disease. J Biol Chem, 1986
(13) Pentchev PG et al. Type C Niemann-Pick disease: a parallel loss of regulatory responses in both the uptake and esterification of low-density lipoprotein-derived cholesterol in cultured fibroblasts. J Biol Chem 261: 16775-16780, 1986
(14) Kitagawa T. An animal model of human acid sphingomyelinase deficiency (Niemann-Pick disease) and the study of its enzyme replaceMent Jpn J Hum Genet 32: 55-69, 1987
(15) Liscum L, Faust JR: Low density lipoprotein (LDL)-mediated suppression of cholesterol synthesis and LDL uptake is defective in Niemann-Pick type C fibroblasts. J Biol Chem 262: 17002-17008, 1987
(16) Blanchette-Mackie EJ et al. Type-C Niemann-Pick disease: low density lipoprotein uptake is associated with premature cholesterol accumulation in the Golgi complex and excessive cholesterol storage in lysosomes. Proc Nat Acad Sci 85: 8022-8026, 1988
(17) Sokol J et al. Type C Niemann-Pick disease: lysosomal accumulation and defective intracellular mobilization of low density lipoprotein cholesterol. J Biol Chem 263: 3411-3417, 1988
(18) Vanier MT et al. Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification: a collaborative study on 70 patients. Clin Genet 33: 331-348, 1988
(19) Fink JK et al. Clinical spectrum of Niemann-Pick disease type C. Neurology 39: 1040-1049, 1989
(20) Omura K et al. Type C Niemann-Pick disease: clinical and biochemical studies on 6 cases. Brain Dev 11: 57-61, 1989
(21) Thomas GH et al. Correction of sphingomyelinase deficiency in Niemann-Pick type C fibroblasts by removal of lipoprotein fraction from culture media. J Inherit Metab Dis 12: 139-151, 1989
(22) Argoff CE et al. Type C Niemann-Pick disease: documentation of abnormal LDL processing in lymphocytes. Biochem Biophys Res Commun 171: 38-45, 1990
(23) Boustany R-MN et al. Ultrastructural findings in skin from patients with Niemann-Pick disease, type C. Pediat Neurol 6: 177-183, 1990
(24) Roff CF et al. Type C Niemann-Pick disease: use of hydrophobic amines to study defective cholesterol transport. Dev Neurosci 13: 315-319, 1991
(25) Sakai Y et al. A molecular genetic linkage map of mouse chromosome 18, including spm, Grl-1, Fim-2/c-fms, and Mbp. Biochem Genet 29: 103-113, 1991
(26) Turpin JC et al. Clinical aspects of Niemann-Pick type C disease in the adult. Dev Neurosci 13: 304-306, 1991
(27) Vanier MT et al. Type C Niemann-Pick disease: biochemical aspects and phenotypic heterogeneity. Dev Neurosci 13: 307-314, 1991
(28) Carstea ED et al. Linkage of Niemann-Pick disease type C to human chromosome 18. Proc Nat Acad Sci 90: 2002-2004, 1993
(29) Kurimasa A et al. Restoration of the cholesterol metabolism in 3T3 cell lines derived from the sphingomyelinosis mouse (spm/spm) by transfer of a human chromosome 18. Hum Genet 92: 157-162, 1993
(30) Brown DE et al. Feline Niemann-Pick disease type C. Am J Path 144: 1412-1415, 1994
(31) Carstea ED et al. Localizing the human Niemann-Pick C gene to 18q11-12. (Abstract) Am J Hum Genet 55 (suppl.): A182, 1994
(32) Ceuterick C et al. Nerve biopsy findings in Niemann-Pick type II (NPC). (Letter) Acta Neuropath 88: 602-603, 1994
(33) Steinberg SJ et al. Complementation studies in Niemann-Pick disease type C indicate the existence of a second group. J Med Genet 31: 317-320, 1994
(34) Auer IA et al. Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropath 90: 547-551, 1995
(35) Vanier MT et al. Genetic heterogeneity in Niemann-Pick C disease: a study using somatic cell hybridization and linkage analysis. Am J Hum Genet 58 (1): 118-25, 1996
(36) Akaboshi S et al. A C57BL/KsJ mouse model of Niemann-Pick disease (spm) belongs to the same complementation group as the major childhood type of Niemann-Pick disease type C. Hum. Genet. 99: 350-353, 1997
(37) Carstea ED et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 277: 228-231, 1997
(38) Greer WL et al. Linkage of Niemann-Pick disease type D to the same region of human chromosome 18 as Niemann-Pick disease type C. Am. J. Hum. Genet. 61: 139-142, 1997
(39) Loftus SK et al. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science 277: 232-235, 1997
(40) Schedin S et al. Peroxisomal impairment in Niemann-Pick type C disease. J. Biol. Chem. 272: 6245-6251, 1997
(41) Greer WL et al. The Nova Scotia (type D) form of Niemann-Pick disease is caused by a 3097G-T transversion in NPC1. Am. J. Hum. Genet. 63: 52-54, 1998
(42) Greer WL et al. Mutations in NPC1 highlight a conserved NPC1-specific cysteine-rich domain. Am. J. Hum. Genet. 65: 1252-1260, 1999
(43) Millat G et al. Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant allele in patients of western European descent and correlates with a classic juvenile phenotype. Am. J. Hum. Genet. 65: 1321-1329, 1999
(42) Morris JA et al. The genomic organization and polymorphism analysis of the human Niemann-Pick C1 gene. Biochem. Biophys. Res. Commun. 261: 493-498, 1999
(44) Patel SC et al. Localization of Niemann-Pick C1 protein in astrocytes: implications for neuronal degeneration in Niemann-Pick type C disease. Proc. Nat. Acad. Sci. 96: 1657-1662, 1999
(45) Watari H et al. Niemann-Pick C1 protein: obligatory roles for N-terminal domains and lysosomal targeting in cholesterol mobilization. Proc. Nat. Acad. Sci. 96: 805-810, 1999
(46) Xie C et al. Cholesterol accumulation in tissues of the Niemann-Pick type C mouse is determined by the rate of lipoprotein-cholesterol uptake through the coated-pit pathway in each organ. Proc. Nat. Acad. Sci. 96: 11992-11997, 1999
(47) Yamamoto T et al. NPC1 gene mutations in Japanese patients with Niemann-Pick disease type C. Hum. Genet. 105: 10-16, 1999
(48) Davies JP et al. Transmembrane molecular pump activity of Niemann-Pick C1 protein. Science 290: 2295-2298, 2000
(49) Erickson RP et al. Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann-Pick C mice. J. Inherit. Metab. Dis. 23: 54-62, 2000
(50) Ioannou YA: The structure and function of the Niemann-Pick C1 protein. Molec. Genet. Metab. 71: 175-181, 2000
(51) Liu Y et al. Alleviation of neuronal ganglioside storage does not improve the clinical course of the Niemann-Pick C disease mouse. Hum. Molec. Genet. 9: 1087-1092, 2000
(52) Imrie J, Wraith JE: Niemann-Pick disease type C. Arch. Dis. Child. 84: 427-429, 2001
(53) Meiner, V et al. Clinical-biochemical correlation in molecularly characterized patients with Niemann-Pick type C. Genet. Med. 3: 343-348, 2001
(54) Millat G et al. Niemann-Pick C1 disease: correlations between NPC1 mutations, levels of NPC1 protein, and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteine-rich luminal loop. Am. J. Hum. Genet. 68: 1373-1385, 2001
(55) Ribeiro I et al. Niemann-Pick type C disease: NPC1 mutations associated with severe and mild cellular cholesterol trafficking alterations. Hum. Genet. 109: 24-32, 2001
(56) Sun X et al. Niemann-Pick C variant detection by altered sphingolipid trafficking and correlation with mutations within a specific domain of NPC1. Am. J. Hum. Genet. 68: 1361-1372, 2001
(57) Zhang M et al. Cessation of rapid late endosomal tubulovesicular trafficking in Niemann-Pick type C1 disease. Proc. Nat. Acad. Sci. 98: 4466-4471, 2001
(58) Bauer, P.; Knoblich, R.; Bauer, C.; Finckh, U.; Hufen, A.; Kropp, J.; Braun, S.; Kustermann-Kuhn, B.; Schmidt, D.; Harzer, K.; Rolfs, A. : NPC1: complete genomic sequence, mutation analysis, and characterization of haplotypes. Hum. Mutat. 19: 30-38, 2002
(59) Imrie, J.; Vijayaraghaven, S.; Whitehouse, C.; Harris, S.; Heptinstall, L.; Church, H.; Cooper, A.; Besley, G. T. N.; Wraith, J. E. : Niemann-Pick disease type C in adults. J. Inherit. Metab. Dis. 25: 491-500, 2002
(60) Kaminski, W. E.; Klunemann, H. H.; Ibach, B.; Aslanidis, C.; Klein, H. E.; Schmitz, G. : Identification of novel mutations in the NPC1 gene in German patients with Niemann-Pick C disease. J. Inherit. Metab. Dis. 25: 385-389, 2002
(61) Saito, Y.; Suzuki, K.; Nanba, E.; Yamamoto, T.; Ohno, K.; Murayama, S. : Niemann-Pick type C disease: accelerated neurofibrillary tangle formation and amyloid beta deposition associated with apolipoprotein E epsilon-4 homozygosity. Ann. Neurol. 52: 351-355, 2002
(62) Vanier, M. T.; Millat, G. : Niemann-Pick disease type C. Clin. Genet. 64: 269-281, 2003
(63) Josephs, K. A.; Matsumoto, J. Y.; Lindor, N. M. : Heterozygous Niemann-Pick disease type C presenting with tremor. Neurology 63: 2189-2190, 2004
(64) Langmade, S. J.; Gale, S. E.; Frolov, A.; Mohri, I.; Suzuki, K.; Mellon, S. H.; Walkley, S. U.; Covey, D. F.; Schaffer, J. E.; Ory, D. S. : Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc. Nat. Acad. Sci. 103: 13807-13812, 2006
(65) Vance, J. E. : Lipid imbalance in the neurological disorder, Niemann-Pick C disease. FEBS Lett. 580: 5518-5524, 2006
(66) Garver, W. S.; Francis, G. A.; Jelinek, D.; Shepherd, G.; Flynn, J.; Castro, G.; Vockley, C. W.; Coppock, D. L.; Pettit, K. M.; Heidenreich, R. A.; Meaney, F. J. The National Niemann-Pick C1 Disease Database: report of clinical features and health problems. Am. J. Med. Genet. 143A: 1204-1211, 2007
(67) Lloyd-Evans, E.; Morgan, A. J.; He, X.; Smith, D. A.; Elliot-Smith, E.; Sillence, D. J.; Churchill, G. C.; Schuchman, E. H.; Galione, A.; Platt, F. M. : Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nature Med. 14: 1247-1255, 2008
(68) Abel, L. A.; Walterfang, M.; Fietz, M.; Bowman, E. A.; Velakoulis, D. : Saccades in adult Niemann-Pick disease type C reflect frontal, brainstem, and biochemical deficits. Neurology 72: 1083-1086, 2009
(69) Spiegel, R.; Raas-Rothschild, A.; Reish, O.; Regev, M.; Meiner, V.; Bargal, R.; Sury, V.; Meir, K.; Nadjari, M.; Hermann, G.; Iancu, T. C.; Shalev, S. A.; Zeigler, M. : The clinical spectrum of fetal Niemann-Pick type C. Am. J. Med. Genet. 149A: 446-450, 2009
(70) Elrick, M. J., Pacheco, C. D., Yu, T., Dadgar, N., Shakkottai, V. G., Ware, C., Paulson, H. L., Lieberman, A. P.Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum. Molec. Genet. 19: 837-847, 2010
(71) Walterfang, M., Fahey, M., Desmond, P., Wood, A., Seal, M. L., Steward, C., Adamson, C., Kokkinos, C., Fietz, M., Velakoulis, D. White and gray matter alterations in adults with Niemann-Pick disease type C: a cross-sectional study.Neurology 75: 49-56, 2010
(72) Wassif, C. A., Cross, J. L., Iben, J., Sanchez-Pulido, L., Cougnoux, A., Platt, F. M., Ory, D. S., Ponting, C., Bailey-Wilson, J. E., Biesecker, L. G., Porter, F. D. High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genet. Med. 18: 41-48, 2016

2010/05/13
2011/07/04
2011/11/14
2016/02/24 ノート/文献追加
2017/08/11 RCV
2020/05/27 ノート追加